Navigation Links
Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results

HILLSIDE, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary of Integrated BioPharma, Inc. , today announced strong positive results in studies of vaccines against HPV, anthrax and plague made using INBP's novel, proprietary AIPwLV(TM) vaccine technology. The studies were conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the Contract Research Organization led by Dr. Vidadi Yusibov, through which BioTech executes its vaccine-related development activities.

The results, reported in the respected peer-reviewed scientific journal Vaccine, demonstrated pre-clinical efficacy of key HPV proteins produced by the AIPwLV(TM) technology, which induced specific immune responses and protected against HPV challenge infection. HPV is the primary etiologic agent of cervical cancer, which represents the third leading cause of cancer-related death among women worldwide. The reported results support the possibility of producing prophylactic and therapeutic HPV vaccines using the AIPwLV(TM) technology.

The studies also demonstrated that other vaccine candidates made using the AIPwLV(TM) technology induced specific immune responses and conferred complete protection against lethal doses of anthrax and plague, two substances considered as likely bioterrorism agents.

"The AIPwLV(TM) technology achieves rapid, high level production of antigens, antibodies and therapeutic proteins in non-genetically modified plants utilizing a proprietary launch-vector technology," said Dr. Yusibov, the Executive Director of CMB. "It offers rapid, unparalleled scalability of vaccine production and cost efficiency, addressing the principal concerns affecting current methods of vaccine production, particularly where large scale or rapid inoculation is desired," added Dr. Yusibov.

About Integrated BioPharma, Inc.

Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

CONTACT: Jeffery Leach, VP, or Dina Masi, CFO, , bothof Integrated BioPharma Inc., +1-888-319-6962

Web site:

Ticker Symbol: (NASDAQ-NMS:INBP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
7. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
8. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
11. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
Post Your Comments:
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):